ctDNA Molecular Response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer

被引：1
|
作者：
Bailleux, Caroline
Bachelot, Thomas
Bidard, Francois-Clement
Hardy-Bessard, Anne-Claire
Bieche, Ivan
Pradines, Anne
Clatot, Florian
Rouge, Thibault De La Motte
Canon, Jean-Luc
Pistilli, Barbara
Chang, Kyle
Quinn, Katie J.
Gustafson, Heather L.
Dalenc, Florence
Foa, Cyril
Ammarguellat, Hanifa
Bernard-Marty, Chantal
Lucas, Brigitte
Barthier, Sophie
Lorchel, Fabrice
Gisserot, Olivier
Arnould, Laurent
Mauduit, Marjorie
Lemonnier, Jerome
Berger, Frederique
Delaloge, Suzette
Andre, Fabrice
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD17-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD17-02
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Neoadjuvant Therapy for weak receptor-positive/HER2-negative Breast Cancer
    Judith Lorenz, Kuenzell
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1124 - 1124
  • [22] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [23] Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC)
    Velimirovic, Marko
    Gerratana, Lorenzo
    Davis, Andrew A.
    Hensing, Whitney L.
    Clifton, Katherine
    Shah, Ami N.
    D'Amico, Paolo
    Dai, Charles S.
    Denault, Elyssa N.
    Ma, Cynthia X.
    Wander, Seth A.
    Juric, Dejan
    Cristofanilli, Massimo
    Chabner, Bruce A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [24] Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer
    Kubo, Makoto
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [25] Evolving treatment patterns in hormone receptor-positive, HER2-negative metastatic breast cancer
    Lankford, M. L.
    Britton, S. L.
    Buettner, A. D.
    Scharf, M.
    Tiscione, B.
    Willey, J. P.
    Mahtani, R. L.
    CANCER RESEARCH, 2019, 79 (04)
  • [26] Clinical considerations for estrogen receptor-negative/ progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer
    Rala de Paula, Bruno Henrique
    Crocamo, Susanne
    Bines, Jose
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [27] Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer
    Rakha, Emad A.
    Agarwal, Devika
    Green, Andrew R.
    Ashankyty, Ibraheem
    Ellis, Ian O.
    Ball, Graham
    Alaskandarany, Mohammed A.
    HISTOPATHOLOGY, 2017, 70 (04) : 622 - 631
  • [28] The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Grinshpun, Albert
    Sandusky, Zachary M.
    Jeselsohn, Rinath
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 169 - 181
  • [29] Response to First-line Recurrence Treatment Influences Survival in Hormone Receptor-positive, HER2-negative Breast Cancer: A Multicenter Study
    Yamamura, Jun
    Kamigaki, Shunji
    Tsujie, Masaki
    Fujita, Junya
    Osato, Hiroki
    Higashi, Chihiro
    Kanaizumi, Hirofumi
    Tanaka, Yumiko
    Hamada, Mika
    Shinzaki, Wataru
    Hashimoto, Yukihiko
    Komoike, Yoshifumi
    IN VIVO, 2019, 33 (01): : 281 - 287
  • [30] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
    Christopher D. Hart
    Ilenia Migliaccio
    Luca Malorni
    Cristina Guarducci
    Laura Biganzoli
    Angelo Di Leo
    Nature Reviews Clinical Oncology, 2015, 12 : 541 - 552
12345